Back
Evoke Pharma 10K Form
Sell
17
EVOK
Evoke Pharma
Last Price:
4.41
Seasonality Move:
8.87%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-14 | 10Q | EVOK/Evoke Pharma Quarterly |
| 2023-11-09 | 10Q | EVOK/Evoke Pharma Quarterly |
| 2023-08-10 | 10Q | EVOK/Evoke Pharma Quarterly |
| 2023-05-15 | 10Q | EVOK/Evoke Pharma Quarterly |
| 2022-11-09 | 10Q | EVOK/Evoke Pharma Quarterly |
| 2022-08-10 | 10Q | EVOK/Evoke Pharma Quarterly |
Receive EVOK News And Ratings
See the #1 stock for the next 7 days that we like better than EVOK
EVOK Financial Statistics
Sales & Book Value
| Annual Sales: | $5.18M |
|---|---|
| Cash Flow: | $-818.7K |
| Price / Cash Flow: | 0 |
| Annual Sales: | $4.90 |
| Price / Book: | 1.49 |
Profitability
| EPS (TTM): | -11.03000 |
|---|---|
| Net Income (TTM): | $-6.15M |
| Gross Margin: | $4.98M |
| Return on Equity: | -433.12% |
| Return on Assets: | -57.27% |
Evoke Pharma Earnings Forecast
Key Evoke Pharma Financial Ratios
- The Gross Profit Margin over the past 13 years for EVOK is 96.10%.
- The Selling, General & Administrative Expenses for EVOK have been equal to 236.03% of Gross Profit Margin.
- The Research & Development expenses have been 3.51% of Revenue.
- The Interest Expense is -6.42% of Operating Income.
- The Net Earning history of EVOK is -150.41% of Total Revenues.
- Per Share Earnings over the last 13 years have been positive in 10 years.
Evoke Pharma Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Pharmaceuticals |
| Sector: | Health Care |
| Current Symbol: | EVOK |
| CUSIP: | 30049G |
| Website: | evokepharma.com |
Debt
| Debt-to-Equity Ratio: | 1.14 |
|---|---|
| Current Ratio: | 1.44 |
| Quick Ratio: | 1.37 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 9.15 |
EVOK Technical Analysis vs Fundamental Analysis
Sell
17
Evoke Pharma (EVOK)
is a Sell
Is Evoke Pharma a Buy or a Sell?
-
Evoke Pharma stock is rated a Sell
The current Evoke Pharma [EVOK] share price is $4.39. The Score for EVOK is 17, which is 66% below its historic median score of 50, and infers higher risk than normal.